What Are the 4 Stages of Liver Cirrhosis?

Liver cirrhosis is classified into four clinical stages based on the presence or absence of specific complications, primarily enlarged veins in the esophagus or stomach (varices), fluid buildup in the abdomen (ascites), and bleeding from those enlarged veins. The first two stages are grouped under “compensated” cirrhosis, meaning the liver is scarred but still functioning well enough that you feel relatively normal. The last two stages fall under “decompensated” cirrhosis, where the liver can no longer keep up and serious symptoms emerge. The distinction between these stages matters because each carries a very different outlook and calls for different treatment decisions.

How the Four Stages Break Down

The staging system used most often in clinical research divides cirrhosis by the complications that have appeared so far. Stage 1 is compensated cirrhosis with no varices. Stage 2 is compensated cirrhosis with varices present. Stage 3 is decompensated cirrhosis marked by ascites, which is the first major complication most people develop. Stage 4 is decompensated cirrhosis with gastrointestinal bleeding from varices, with or without ascites or other complications.¹ Some researchers have proposed a five-stage model that separates a first decompensating event from subsequent ones, reflecting the reality that each additional complication worsens prognosis sharply.² But the four-stage framework remains the most widely referenced in clinical guidelines and patient education.

What drives this staging is portal hypertension, the abnormally high blood pressure in the vein that carries blood from the gut to the liver. As scar tissue accumulates, it stiffens the liver and resists blood flow. Pressure builds. That pressure eventually forces blood into alternative routes, creating varices, and pushes fluid into the abdominal cavity, causing ascites. Every stage transition is essentially a new consequence of portal hypertension reaching a threshold the body can no longer compensate for.

Stages 1 and 2, the Compensated Phase

In stage 1, the liver is cirrhotic on biopsy or imaging, but you would not know it from how you feel. People with compensated cirrhosis are largely asymptomatic with preserved liver function.³ Blood tests may look mostly normal, and daily life is not disrupted. The liver has remarkable reserve capacity, so a significant amount of scarring can accumulate before the organ actually starts falling behind on its workload. Many people are diagnosed at this stage only because imaging done for an unrelated reason reveals liver changes, or because a screening blood test raises a flag.

Stage 2 is still compensated, but an endoscopy reveals varices in the esophagus or stomach. You still feel fine, and your liver function has not obviously declined, but the presence of varices signals that portal hypertension is climbing. This matters because it changes what your doctor does next. In patients with hepatitis C-related cirrhosis, for example, achieving viral clearance at stage 1 made patients less likely to develop varices in the first place, while those already at stage 2 had a different risk profile.⁴ Once varices are found, beta-blocker medications or endoscopic banding are typically started to reduce the chance of bleeding. You can live in stages 1 or 2 for years, sometimes over a decade, especially if the underlying cause of the cirrhosis is treated or controlled.

Stages 3 and 4, the Decompensated Phase

The transition from compensated to decompensated cirrhosis is one of the most important inflection points in the disease. Decompensation is defined by the development of ascites, variceal hemorrhage, or hepatic encephalopathy.⁵ Stage 3 is typically marked by ascites as the first sign of decompensation. The belly swells with fluid, sometimes holding several liters. It can be uncomfortable, make breathing difficult, and carry a risk of spontaneous infection. Diuretics and salt restriction are the first-line treatments, and when those are not enough, the fluid is drained directly with a needle procedure.

Stage 4 adds variceal hemorrhage to the picture. Bleeding from varices is a medical emergency, involving vomiting blood or passing dark, tarry stools. Variceal hemorrhage, along with ascites and encephalopathy, defines cirrhosis decompensation and is driven by portal hypertension.⁶ Survival drops considerably once you reach decompensated stages. Where compensated cirrhosis may carry a median survival measured in a decade or more, decompensated cirrhosis often narrows that window to a few years without transplantation, and each additional complication compresses the timeline further.

How Doctors Measure Severity Beyond the Stages

The four-stage framework tells you which complications have appeared, but it does not capture exactly how sick the liver is. For that, doctors rely on scoring systems. The two most widely used are the Child-Pugh score and the MELD score, both of which have been widely used for assessing prognosis in liver cirrhosis.⁷

The Child-Pugh score groups patients into three classes (A, B, and C) based on a combination of blood tests and clinical findings. In one study, patients in Class A had a survival rate around 88%, while Classes B and C were considerably lower at roughly 30%.⁸ The MELD score, used by transplant centers to prioritize patients on the waiting list, is a number calculated from kidney function, clotting ability, and bilirubin. A higher MELD means sicker. In that same study, about half of patients had a MELD/Na score above 20, and nearly 60% died within 12 months, reflecting a population with advanced disease.

These scoring systems and the four clinical stages overlap but are not interchangeable. A person in stage 2 (compensated with varices) could have a relatively favorable MELD score, while a stage 3 patient with stubborn ascites might score quite high. The clinical stages describe what has happened; the scoring systems try to predict what will happen next.

Hepatic Encephalopathy

One complication that does not get its own stage number but profoundly affects quality of life is hepatic encephalopathy. When the liver cannot properly clear ammonia from the blood, ammonia crosses into the brain and gets taken up by brain cells called astrocytes. The astrocytes convert ammonia to another substance, but the process causes them to swell with water, disrupting normal brain function.⁹ Symptoms range from mild confusion, forgetfulness, and personality changes to full disorientation, slurred speech, and eventually coma in severe cases.

What makes encephalopathy tricky is that the mild forms are easy to miss. A person with early encephalopathy might simply seem slower or more irritable, and both patients and families may chalk it up to fatigue or aging. Formal testing often reveals cognitive impairment that is not obvious during a casual conversation. The standard treatment is lactulose, a syrup that helps the gut excrete ammonia more rapidly, and the antibiotic rifaximin, which reduces the ammonia-producing bacteria in the intestine. Episodes tend to come and go, often triggered by infections, constipation, or dehydration, but frequent episodes signal that the liver is losing ground.

Hepatorenal Syndrome

Another feared complication of advanced cirrhosis is hepatorenal syndrome, in which the kidneys begin to fail even though the kidneys themselves are structurally normal. The problem is not kidney disease per se; it is that worsening liver dysfunction and portal hypertension cause blood vessels outside the liver to widen while the blood vessels feeding the kidneys clamp down. The kidneys simply stop receiving enough blood flow to filter properly.¹⁰ The cascade involves falling blood pressure, activation of stress hormones, and severe constriction of the kidney’s own blood supply.¹¹

Hepatorenal syndrome usually appears in stage 3 or 4 patients with refractory ascites, and it carries a grim prognosis without rapid treatment. Medications that constrict the widened peripheral blood vessels and redirect flow to the kidneys are the bridge therapy, but the only definitive fix is a liver transplant. If you are in decompensated cirrhosis and your kidney function starts declining without an obvious reason like dehydration or a medication side effect, hepatorenal syndrome is one of the first things doctors will investigate.

Acute-on-Chronic Liver Failure

Sometimes a person with cirrhosis experiences a sudden, dramatic worsening over days to weeks, well beyond the usual pace of the disease. This is called acute-on-chronic liver failure, and it is characterized by acute deterioration of cirrhosis, a massive inflammatory response, and rapidly developing organ failure.¹² Common triggers include bacterial infections, heavy alcohol use, reactivation of hepatitis B, or drug-induced liver injury. The immune system goes into overdrive, producing inflammation that damages organs beyond the liver, including the kidneys, brain, and lungs.¹³

Acute-on-chronic liver failure does not fit neatly into the four-stage model because it can strike patients at various stages and send them from a stable condition to life-threatening multi-organ failure within days. Short-term mortality is high, and intensive care is typically required. It is one of the reasons doctors stress infection prevention and alcohol abstinence in cirrhosis patients, even those who feel well. A seemingly minor infection or a weekend of drinking can be the trigger that tips the balance.

The Role of Inflammation Even in Early Stages

One finding that has shifted how researchers think about cirrhosis is that bacterial translocation, the movement of gut bacteria or their products into the bloodstream, begins well before decompensation. A study found that this occurs already in early stages of advanced chronic liver disease and triggers a systemic inflammatory response involving specific signaling molecules.¹⁴ This low-grade inflammation may help explain why some people with seemingly compensated disease deteriorate faster than others and why infections are so dangerous at every stage. The gut barrier weakens as portal hypertension worsens, letting bacteria slip across more easily, which feeds a cycle of inflammation and further liver damage.

Detecting Cirrhosis Before Symptoms Appear

Because stages 1 and 2 often produce no symptoms, catching cirrhosis early depends heavily on screening tools. Liver biopsy has long been the gold standard, but it is invasive and not practical for routine use. A non-invasive alternative called transient elastography (commonly known by the brand name FibroScan) uses ultrasound-based vibrations to measure liver stiffness. In a large U.S. study, it showed excellent diagnostic accuracy for cirrhosis, with a stiffness cutoff of about 12.8 kPa yielding roughly 84% sensitivity and 86% specificity for identifying stage-four fibrosis.¹⁵

Blood-based scoring tools like FIB-4 (a simple calculation using age, platelet count, and liver enzymes) are also used as initial screens. They are less accurate individually, but combining a blood score with elastography improves the overall picture. One study in patients with fatty liver disease found that FibroScan correctly identified about 46% of patients with advanced fibrosis as having it, while FIB-4 caught only about 17%.¹⁶ That may sound low, but these tools are designed mainly to rule out advanced disease in people at low risk, not to confirm it in isolation. A high score on either test prompts further evaluation, while a low score offers meaningful reassurance. The key takeaway for anyone with risk factors like chronic hepatitis, heavy alcohol use, or metabolic syndrome is that screening exists and can catch cirrhosis while it is still in the compensated, treatable window.

Can Cirrhosis Be Reversed?

The textbook answer used to be no. Cirrhosis was considered the irreversible endpoint of liver disease. That view has changed. Multiple clinical studies have shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples when the underlying cause is treated.¹⁷ There is abundant clinical evidence supporting reversibility across different causes of liver disease, including viral hepatitis, autoimmune conditions, and metabolic liver disease.¹⁸

One of the most striking examples comes from a study of hepatitis B patients treated with the antiviral drug tenofovir. Among patients who had cirrhosis at the start of the study, about three-quarters no longer had cirrhosis on follow-up biopsy after five years of treatment.¹⁹ Similar improvements have been documented in hepatitis C patients who achieve viral cure and in people with alcohol-related liver disease who stop drinking entirely.

Reversal is most likely in early compensated cirrhosis where the scarring has not yet become too dense and the liver architecture has not been completely distorted. Once decompensation has set in and portal hypertension is well established, some improvement is possible, but full reversal becomes much less likely. This is a strong argument for early diagnosis and aggressive treatment of the underlying cause. The liver can heal itself, but only if you give it the opportunity before the damage goes too far.

Interventional Procedures for Portal Hypertension

When medications alone are not enough to control the complications of portal hypertension, a procedure called TIPS (transjugular intrahepatic portosystemic shunt) may be offered. TIPS involves placing a stent inside the liver that creates a new channel for blood to flow through, effectively bypassing the scarred tissue and lowering portal pressure. It is currently indicated as a rescue therapy for variceal bleeding that does not respond to standard treatment, and recent evidence supports using it early (within 72 hours) in high-risk bleeding episodes as a potentially life-saving measure.²⁰ TIPS is also used for refractory ascites that does not respond to diuretics and repeated drainage.

A large study of over 1,100 TIPS recipients found that outcomes varied by the reason the procedure was done. Patients who received TIPS for ascites had a somewhat steady risk of death across different MELD score ranges, while those treated for variceal bleeding saw increasing risk as their MELD scores rose above 20.²¹ The main downside of TIPS is that by diverting blood around the liver, it can worsen hepatic encephalopathy, since less blood gets filtered by whatever liver tissue is still functioning. Modern covered stents have improved durability and reduced the rate of shunt malfunction compared to earlier designs.²²

Liver transplantation remains the definitive treatment for end-stage cirrhosis. It is generally considered when complications become unmanageable, when MELD scores indicate high short-term mortality, or when liver cancer develops within certain criteria. The MELD score is the primary tool used to allocate donor organs in most transplant systems, ensuring that the sickest patients receive priority. While transplantation outcomes have improved dramatically over the decades, the shortage of donor organs means that many patients spend months to years on the waiting list, during which managing complications and maintaining nutrition become critical tasks.

Liver Cancer Screening in Cirrhosis

Cirrhosis of any cause is the single biggest risk factor for developing hepatocellular carcinoma, the most common type of primary liver cancer. Current guidelines recommend that patients with cirrhosis undergo surveillance with an abdominal ultrasound every six months. The annual incidence of liver cancer in cirrhosis varies by risk level. A cost-effectiveness analysis stratified patients into risk categories and found annual incidence rates of about 4.9% in the high-risk group, about 3.3% in the intermediate group, and about 0.8% in the low-risk group.²³ Even in the low-risk group, the rate is high enough that routine screening is recommended. Cancer caught early in a cirrhotic liver can sometimes be treated with ablation, radiation, or resection, and in some cases makes a patient eligible for transplantation under specific criteria.

Muscle Loss and Physical Decline

A complication that gets far less attention than bleeding or ascites but powerfully affects outcomes is sarcopenia, the progressive loss of muscle mass and strength. The liver is central to protein metabolism, so as it fails, the body increasingly breaks down its own muscle for energy. Sarcopenia is associated with lower survival in patients with cirrhosis, independent of other risk factors such as age and MELD score.²⁴ Patients with sarcopenia tolerate complications poorly, recover more slowly from infections and procedures, and face higher mortality on transplant waiting lists.

Maintaining muscle mass in cirrhosis is harder than it sounds. Appetite is often reduced, the body does not process nutrients efficiently, and many patients are told to restrict salt (for ascites) or protein (an outdated recommendation that most guidelines have since revised). Current best practice encourages frequent small meals, a late-night snack to reduce overnight fasting, and adequate protein intake unless encephalopathy is truly uncontrollable. Resistance exercise, even modest amounts, has shown benefits in cirrhosis patients and is increasingly recommended.

Sleep Disruption in Cirrhosis

Sleep problems are common in cirrhosis and contribute to a quality of life burden that staging systems do not capture. The most frequent complaints are insomnia, excessive daytime sleepiness, and a flipped sleep-wake cycle where the person is drowsy during the day and wide awake at night. The underlying causes are complex and likely involve disrupted melatonin metabolism, altered blood sugar regulation, and changes in thermoregulation and appetite hormones.²⁵ These sleep disturbances can overlap with or be mistaken for hepatic encephalopathy, making it important to distinguish between the two. Sleep-wake inversion on its own does not necessarily mean encephalopathy is worsening, but it should prompt a clinical evaluation. For patients and families, the day-to-day reality of fragmented sleep, constant fatigue, and cognitive fog is often more distressing than the complications that appear on lab reports.